We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Zoetis Q1 Earnings Lag Estimates, 2026 View Cut, Stock Down
Read MoreHide Full Article
Key Takeaways
Zoetis Q1 revenues rose 3% year over year but missed estimates on weak U.S. demand.
ZTS lowered 2026 revenue guidance to $9.68B-$9.96B while adjusted EPS was cut to $6.85-$7.00.
U.S. companion animal sales fell 11% in Q1 due to competition and macro-driven price sensitivity.
Zoetis, Inc. (ZTS - Free Report) delivered first-quarter 2026 adjusted earnings (excluding one-time items) of $1.53 per share, which missed the Zacks Consensus Estimate of $1.61. In the year-ago quarter, the company had delivered adjusted earnings of $1.48 per share.
Total revenues grew 3% year over year to $2.26 billion in the first quarter, which marginally missed the Zacks Consensus Estimate of $2.30 billion. In the year-ago quarter, the company reported total revenues of $2.22 billion.
Shares of Zoetis were down during the pre-market hours today following the weaker-than-expected results as well as the reduced 2026 guidance.
Year to date, shares of Zoetis have plunged 11.6% compared with the industry’s decline of 1.3%.
Image Source: Zacks Investment Research
ZTS’ Q1 Results in Detail
Zoetis derives the majority of its revenues from a diversified product portfolio of medicines and vaccines used to treat and protect livestock and companion animals. The company reports business results under two geographical operating segments — the United States and International.
Revenues from the U.S. segment decreased 8% year over year to $1.09 billion in the reported quarter, missing the Zacks Consensus Estimate of $1.20 billion.
Sales of companion animal products in the U.S. region declined 11% year over year to $865 million, owing to softer end-market demand and an increasingly competitive landscape. Zoetis’ key dermatology franchise and Simparica Trio faced heightened competitive pressure and persistent macroeconomic-driven price sensitivity. Also, generic competition for the Convenia and Cerenia brands, as well as lower sales of ZTS’ monoclonal antibody product for osteoarthritis (OA) pain, Librela, for dogs resulted in the decline.
Sales of livestock products in the United States increased 7% in the first quarter to $225 million. The increase was mainly due to broad-based strength across cattle, poultry and swine products.
Revenues in the International segment increased 17% year over year on a reported basis and 10% on an operational basis to $1.15 billion, beating the Zacks Consensus Estimate of $1.08 billion.
Ex-U.S. sales of companion animal products rose 15% on a reported basis and 7% operationally to $654 million, driven by growth in the parasiticides portfolio, including Simparica Trio, along with contributions from diagnostics, vaccines, and the timing of price increases.
Livestock product sales increased 19% year over year on a reported basis and 14% operationally to $495 million, driven by broad-based growth across all core species, including cattle, swine, poultry and fish.
ZTS’ 2026 Guidance
Zoetis lowered its earnings and revenue outlook for 2026.
The company now expects revenues to be in the range of $9.68 billion and $9.96 billion, reflecting an expected operational growth of 2-5%.
Previously, the company projected revenues between $9.825 billion and $10.025 billion, representing an expected operational growth of 3-5%.
Adjusted earnings are now expected in the range of $6.85-$7.00 per share in 2026, compared with the previous expectation of $7.00-$7.10 per share.
Over the past 60 days, estimates for Agenus’ 2026 earnings per share have risen from 54 cents to $1.30, while loss per share estimates for 2027 have narrowed from $1.91 to $1.52 during the same time. AGEN shares have surged 23.9% year to date.
Agenus’ earnings beat estimates in two of the trailing four quarters, while missing the same on the remaining two occasions, with the average surprise being 31.42%.
Over the past 60 days, 2026 loss per share estimates for AnaptysBio have narrowed from $1.42 to $1.40, while estimates for 2027 have moved from a loss of $4.59 per share to earnings of $3.01 during the same time. ANAB stock has increased 38.9% year to date.
AnaptysBio’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 59.70%.
Over the past 60 days, 2026 loss per share estimates for Amarin have narrowed from $7.01 to $6.36, while the same for 2027 have narrowed from $5.50 to $4.64 during the same time. AMRN stock has risen 6.8% year to date.
Amarin's earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average surprise being 50.02%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Shutterstock
Zoetis Q1 Earnings Lag Estimates, 2026 View Cut, Stock Down
Key Takeaways
Zoetis, Inc. (ZTS - Free Report) delivered first-quarter 2026 adjusted earnings (excluding one-time items) of $1.53 per share, which missed the Zacks Consensus Estimate of $1.61. In the year-ago quarter, the company had delivered adjusted earnings of $1.48 per share.
Total revenues grew 3% year over year to $2.26 billion in the first quarter, which marginally missed the Zacks Consensus Estimate of $2.30 billion. In the year-ago quarter, the company reported total revenues of $2.22 billion.
Shares of Zoetis were down during the pre-market hours today following the weaker-than-expected results as well as the reduced 2026 guidance.
Year to date, shares of Zoetis have plunged 11.6% compared with the industry’s decline of 1.3%.
Image Source: Zacks Investment Research
ZTS’ Q1 Results in Detail
Zoetis derives the majority of its revenues from a diversified product portfolio of medicines and vaccines used to treat and protect livestock and companion animals. The company reports business results under two geographical operating segments — the United States and International.
Revenues from the U.S. segment decreased 8% year over year to $1.09 billion in the reported quarter, missing the Zacks Consensus Estimate of $1.20 billion.
Sales of companion animal products in the U.S. region declined 11% year over year to $865 million, owing to softer end-market demand and an increasingly competitive landscape. Zoetis’ key dermatology franchise and Simparica Trio faced heightened competitive pressure and persistent macroeconomic-driven price sensitivity. Also, generic competition for the Convenia and Cerenia brands, as well as lower sales of ZTS’ monoclonal antibody product for osteoarthritis (OA) pain, Librela, for dogs resulted in the decline.
Sales of livestock products in the United States increased 7% in the first quarter to $225 million. The increase was mainly due to broad-based strength across cattle, poultry and swine products.
Revenues in the International segment increased 17% year over year on a reported basis and 10% on an operational basis to $1.15 billion, beating the Zacks Consensus Estimate of $1.08 billion.
Ex-U.S. sales of companion animal products rose 15% on a reported basis and 7% operationally to $654 million, driven by growth in the parasiticides portfolio, including Simparica Trio, along with contributions from diagnostics, vaccines, and the timing of price increases.
Livestock product sales increased 19% year over year on a reported basis and 14% operationally to $495 million, driven by broad-based growth across all core species, including cattle, swine, poultry and fish.
ZTS’ 2026 Guidance
Zoetis lowered its earnings and revenue outlook for 2026.
The company now expects revenues to be in the range of $9.68 billion and $9.96 billion, reflecting an expected operational growth of 2-5%.
Previously, the company projected revenues between $9.825 billion and $10.025 billion, representing an expected operational growth of 3-5%.
Adjusted earnings are now expected in the range of $6.85-$7.00 per share in 2026, compared with the previous expectation of $7.00-$7.10 per share.
Zoetis Inc. Price, Consensus and EPS Surprise
Zoetis Inc. price-consensus-eps-surprise-chart | Zoetis Inc. Quote
ZTS’ Zacks Rank and Stocks to Consider
Zoetis currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Agenus (AGEN - Free Report) , AnaptysBio (ANAB - Free Report) and Amarin (AMRN - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Agenus’ 2026 earnings per share have risen from 54 cents to $1.30, while loss per share estimates for 2027 have narrowed from $1.91 to $1.52 during the same time. AGEN shares have surged 23.9% year to date.
Agenus’ earnings beat estimates in two of the trailing four quarters, while missing the same on the remaining two occasions, with the average surprise being 31.42%.
Over the past 60 days, 2026 loss per share estimates for AnaptysBio have narrowed from $1.42 to $1.40, while estimates for 2027 have moved from a loss of $4.59 per share to earnings of $3.01 during the same time. ANAB stock has increased 38.9% year to date.
AnaptysBio’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 59.70%.
Over the past 60 days, 2026 loss per share estimates for Amarin have narrowed from $7.01 to $6.36, while the same for 2027 have narrowed from $5.50 to $4.64 during the same time. AMRN stock has risen 6.8% year to date.
Amarin's earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average surprise being 50.02%.